Journal
JOURNAL OF VIROLOGY
Volume 79, Issue 2, Pages 955-965Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.79.2.955-965.2005
Keywords
-
Categories
Funding
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI056354, P01AI026507] Funding Source: NIH RePORTER
- NIAID NIH HHS [N01AI30034, P01 AI056354, P01-AI026507, P01 AI026507, P01-AI56354] Funding Source: Medline
Ask authors/readers for more resources
Gene transfer vectors based on recombinant adeno-associated virus (rAAV) are simple, versatile, and safe. While the conventional applications for rAAV vectors have focused on delivery of therapeutic genes, we have developed the system for delivery of vaccine antigens. In particular, we are interested in generating rAAV vectors for use as a prophylactic human immunodeficiency virus type I (HIV-1) vaccine. To that end, we constructed vaccine vectors that expressed genes from the simian immunodeficiency virus (SIV) for evaluation in the monkey SIV model. After a single intramuscular dose, rAAV/SIV vaccines elicited SIV-specific T cells and antibodies in macaques. Furthermore, immunized animals were able to significantly restrict replication of a live, virulent SIV challenge. These data suggest that rAAV vaccine vectors induced biologically relevant immune responses, and thus, warrant continued development as a viable HIV-1 vaccine candidate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available